MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Post date May 12, 2025 ← MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 → MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
